KKR Real Estate Finance Trust is embarking on what CEO Matt Salem calls a "year of transition," implementing an aggressive strategy to shed troubled assets and reposition its portfolio toward higher-quality loans.
The commercial mortgage real estate investment trust announced plans to resolve most of its watch list loans and liquidate multiple properties it took back throughout 2026, aiming to unlock embedded value.
"Through execution of our business plans, we have positioned much of our [real estate owned] portfolio for liquidity this year," Salem told investors during the REIT’s fourth quarter earnings last week. "Additionally, we are going to implement an aggressive resolution strategy for a significant portion of our watch list assets and select office assets."
KKR Real Estate Finance Trust representatives did not respond to a request for further comment.
The announcement comes as the firm, known as KREF, grapples with mounting credit challenges. The company downgraded its $401 million loan on a Cambridge, Massachusetts, life science property at 441 Morgan Ave., and a San Diego multifamily property loan to the lowest risk rating during the fourth quarter, booking $44 million in loss provisions. Another downgrade is expected in the first quarter for a Boston life science building loan currently in modification discussions.
KREF's short-term real estate owned liquidation targets include a West Hollywood luxury condominium project, a Portland, Oregon, redevelopment, a Raleigh multifamily property and a Philadelphia office building. The company expects to make "good headway" on these assets through partial or complete sales in 2026, Salem said.
A separate loan on a Mountain View, California, office property presents a more complex timeline. While market conditions are "improving meaningfully" and KREF is engaged with potential tenants, management indicated that any monetization would likely occur after 2026 to allow for capital expenditures and tenant improvement work following lease execution, the REIT reported. Salem suggested the property carries "significant value" above its current book value.
Exposure to the life science sector remains a particular concern. Management said it expects an extended recovery period — potentially five years or more — but expressed willingness to be patient on high-quality Seattle and Boston assets. The company is pursuing loan modifications that would require substantial sponsor capital commitments to reduce the cost basis, Salem said.
Life sciences lab construction has surged in recent years, according to CoStar analysis. At its peak in 2023, the lab pipeline reached nearly 16 million square feet, four times the amount being built just five years earlier. Lab construction has fallen more than 50% in the two years since, as the construction wave produced a glut at the same time as demand from life sciences organizations has evaporated.
Salem drew a distinction between past office problems and new office originations, emphasizing the REIT's focus on "newer, high-quality assets" with "stabilized cash flows" and "long-term leases in place" in strong markets.
KREF closed its first loans in Europe in 2025, representing an effort to diversify geographically, the company also disclosed.
Financial services company Keefe, Bruyette & Woods reduced its earnings per share estimate on KREF based on its increase in non-earning assets and elevated repayments, wrote Jade Rahmani, an analyst for the firm. KBW also increased the amount of money KREF would have to set aside due to KREF's forecast of the first quarter life science downgrade and assumed loan dispositions in 2026.
"Given lower earnings, we assume the quarterly dividend is reduced to $0.17 from $0.25 in 2026 and believe KREF's long-run [earnings per share] will exceed that once the portfolio is repositioned," Rahmani wrote.
The repositioning strategy will pressure near-term earnings, Salem acknowledged, noting that the board is evaluating the dividend as part of broader capital allocation discussions. The company paid a $0.25 quarterly dividend but reported distributable earnings of just $0.22 per share in the fourth quarter.
The REIT anticipates over $1.5 billion in loan repayments during 2026, exceeding activity in each of the past two years. The company maintains near-record liquidity of $880 million and continues opportunistic share repurchases, having bought back $43 million in stock during 2025 at an average price of $9.35.
"My expectation is if we show up with a clean portfolio, a newer portfolio, the market will price it," Salem said. "I think the market is efficient and will recognize the steps that we've taken and the new portfolio that we've been able to create."